Yes. But this depends upon what infection and the sensitivities of the strain of pseudomonas with which the patient is infected.
Aztreonam. Is the only monobactam available in the usa. It does have activity against pseudomonas but hospital strains may be resistant.
Maybe. Monobactams are drugs chemically similar to the penicillins. The only commercially available monobactam in the United States is a drug called aztreonam, it is effective against some strains of pseudomonas but not all. Because of this it is more of a second choice agent in those who can not take drugs that have greater efficacy because of allergies etc.
Sometimes. There are several kinds or "generations" of cephalosporins antibiotics, which are antibiotics that are chemically related to penicillin. Some of the drugs in this class are highly effective against pseudomonas and some are not. In fact this can vary to some degree depending on the antibiotic sensitivities specific to the pseudomonas strains prevalent in a particular hospital or community.
Yes some. There are many different cephalosporin antibiotics. Many are not effective against ps. Aer. Those that are active against this organism are Fortaz (ceftazidime) and maxipime (cefepime).
Yes. Amino glycosides are often very effective against pseudomonas.
Pseudomonas. They can be among the antibiotics used.
Bacteria. Pseudomonas is a gram negative rod (classification of bacteria). When we see it, it is usually in the hospital in wound infections. It is usually treated successfully with dressing changes and antibiotics.
Varies. This bacteria is a relatively common cause of hospital acquired infections. It is also an important cause of infection in patients with cystic fibrosis. To get an idea of how common in hospitalized patients it is seen in up to 4/1000 patient discharges from the hospital and is responsible for about 10% of hospital acquired infections.
Ubiquitus. This bacteria is common world-wide and found in soil, water, your GI tract and elsewhere.
See below. Infections with ps. Aer have remained constant in incidence and tissue sites during the last 40 years. In the usa ps. Aer accounted for 18% of hospital acquired pneumonias, 16% of hospital acquired uti's, 9.5% of surgical site infections and 3.4% of bloodstream infections. There is a problem with increasing antibiotic resistance in this organism.